Second Quarter Reflects Increases In Pipeline Activity. Ocugen reported a loss of $19.5 million or $(0.09) per share, greater than our estimated loss of $16.7 million or $(0.07) per share. The difference was due to higher expenses from clinical trials and increased headcount as the company added development staff. The company ended the quarter with $115.0 million in cash.Covaxin Clinical Studies Move Forward. Ocugen is currently conducting a Phase 2/3 immuno-bridging study for US approval. Discussions continue with Health Canada regarding additional information that may be required for Canadian approval. In Mexico, Covaxin has received emergency use authorization for adults, with submission for pediatric use under review. Due to the shortages of other COVID-19 vaccines in Mexico, this territory is a near-term opportunity for Covaxin. Read More >>